[
  {
    "date": "2022-12-31",
    "symbol": "REPCF",
    "period": "FY",
    "entityregistrantname": "REPLICEL LIFE SCIENCES INC.",
    "entitycentralindexkey": 1205059,
    "documentperiodenddate": "                                                December 31, 2022                                            ",
    "documenttype": "20-F",
    "currentfiscalyearenddate": "December 31",
    "amendmentflag": "false",
    "documentfiscalperiodfocus": "FY",
    "documentfiscalyearfocus": 2022,
    "entitycurrentreportingstatus": "Yes",
    "entityfilercategory": "Non-accelerated filer",
    "documentannualreport": "true",
    "documenttransitionreport": "[ ]",
    "documentregistrationstatement": "[ ]",
    "entityfilenumber": "000-50112",
    "entityincorporationstatecountrycode": "British Columbia",
    "entitywellknownseasonedissuer": "No",
    "entityvoluntaryfilers": "No",
    "entityinteractivedatacurrent": "Yes",
    "entityemerginggrowthcompany": "[ ]",
    "entityshellcompany": "No",
    "contactpersonnelname": "Andrew Schutte",
    "cityareacode": 604,
    "localphonenumber": "248-8730",
    "entityaddressaddressline1": "Suite 900 - 570 Granville Street",
    "entityaddresscityortown": "Vancouver",
    "entityaddressstateorprovince": "British Columbia",
    "entityaddresscountry": "Canada",
    "entityaddresspostalzipcode": "V6C 3P1",
    "contactpersonnelfaxnumber": "(604) 248-8690",
    "documentaccountingstandard": "International Financial Reporting Standards",
    "auditorname": "Mao & Ying LLP",
    "auditorlocation": "Vancouver, Canada",
    "auditorfirmid": 6976,
    "cashandcashequivalents": 413025,
    "shortterminvestmentsclassifiedascashequivalents": 17250,
    "currenttaxassetscurrent": 46795,
    "currentprepaidexpenses": 123233,
    "currentcontractassets": 35374,
    "currentassets": 635677,
    "noncurrentcontractassets": 160103,
    "propertyplantandequipment": 1285,
    "assets": 798218,
    "tradeandothercurrentpayables": 1029726,
    "currentcontractliabilities": 353735,
    "preferenceshares": 927935,
    "currentliabilities": 2072751,
    "longtermborrowings": 40956,
    "deferredgovernmentgrantincomenoncurrent": 5636,
    "noncurrentputliability": 3393337,
    "noncurrentcontractliabilities": 1601010,
    "noncurrentroyaltypayable": 1623088,
    "liabilities": 6713479,
    "issuedcapital": 31661019,
    "additionalpaidincapital": 5398590,
    "retainedearnings": -42974870,
    "equity": -42974870,
    "equityandliabilities": 798218,
    "licencefeeincome": 353735,
    "researchanddevelopmentexpense": 623964,
    "sellinggeneralandadministrativeexpense": 1125282,
    "profitlossfromoperatingactivities": -1395511,
    "accretiononpreferenceshares": 77904,
    "accretiononcebaloan": 6701,
    "accretiononputliability": 256185,
    "accretiononroyaltypayable": 498534,
    "gainslossesonexchangedifferencesontranslationrecognisedinprofitorloss": -288905,
    "gainfromchangeinroyaltypayable": 3310875,
    "revenuefromgovernmentgrants": 2818,
    "investmentincome": 43,
    "profitloss": -743228,
    "dilutedearningslosspershare": -0.02,
    "adjustedweightedaverageshares": 37767620,
    "adjustmentsforaccretionandaccrueddividends": 77904,
    "adjustmentsforunrealisedforeignexchangelossesgains": 253024,
    "adjustmentsforamortizationofcontractasset": 35372,
    "revenuefromcontractliability": 353735,
    "adjustmentsfordepreciationandamortisationexpense": 839,
    "adjustmentsforsharebasedpayments": 69056,
    "adjustmentsfordecreaseincreaseinsalestaxesrecoverable": -20928,
    "adjustmentsfordecreaseincreaseinprepaidexpensesanddeposits": -29870,
    "adjustmentsforincreasedecreaseintradeaccountpayable": 321162,
    "adjustmentsforincreasedecreaseindeferredgovernmentgrant": -2818,
    "cashflowsfromusedinoperatingactivities": -1409453,
    "grossproceedsfrominvestment": 2698884,
    "proceedsfromissuingshares": 841965,
    "cashflowsfromusedinfinancingactivities": 1601290,
    "increasedecreaseincashandcashequivalents": 191837,
    "numberofsharesoutstanding": 47597327,
    "increasedecreasethroughsharebasedpaymenttransactions": 69506,
    "increasedecreasethroughsharesissuedten": 759325,
    "increasedecreasethroughsharesissuedsharesten": 4218470,
    "increasedecreasethroughsharesissuedeleven": 841965,
    "increasedecreasethroughsharesissuedshareseleven": 8419650,
    "increasedecreasethroughcontributedsurpluswarrantreserve": 231757,
    "numberofoutstandingshareoptions": 2675000,
    "weightedaverageexercisepriceofshareoptionsoutstandinginsharebasedpaymentarrangement2019": 0.43,
    "numberofshareoptionsforfeitedinsharebasedpaymentarrangement": 150000,
    "numberofshareoptionsexercisableinsharebasedpaymentarrangement": 2402500,
    "weightedaverageexercisepriceofshareoptionsexercisableinsharebasedpaymentarrangement2019": 0.41,
    "numberofoutstandingwarrants": 8138614,
    "weightedaverageexercisepriceofwarrantsoutstandinginsharebasedpaymentarrangement": 0.29,
    "numberofwarrantsgrantedinsharebasedpaymentarrangement": 4209825,
    "weightedaverageexercisepriceofwarrantsgrantedinsharebasedpaymentarrangement": 0.2,
    "guaranteedinvestmentcertificateinterestrate": 0.022000000000000002,
    "securitiesexcludedfromcomputationofearningspershareamount": 8138615,
    "preferencesharesredemptionperiod": 5,
    "preferencestockredemptionpricepershare": 0.74,
    "fairvalueputliabilityrepayable": 3393337,
    "putliabilityrepayableperiod": 8.5,
    "putliabilitydiscountedrate": 0.23,
    "amortizedcostputliabilityrepayable": 520426,
    "putliabilityaccretionexpense": 256185,
    "numberofsharesissued": 47597327,
    "numberofsharesissuedsubjecttoputoption": 3571888,
    "descriptionofstockoptionplan": "On May 21, 2014, the Company approved a Stock Option Plan whereby the Company may grant stock options to directors, officers, employees and consultants. The maximum number of shares reserved for issue under the plan cannot exceed 10% of the outstanding common shares of the Company as at the date of the grant. The stock options can be exercisable for a maximum of 10 years from the grant date and with various vesting terms.",
    "weightedaverageremainingcontractuallifeofoutstandingshareoptions2019": 2.36,
    "unrecognizedstockbasedcompensation": 14978,
    "increasedecreaseinnumberofordinarysharesissued": 3986684,
    "commanstocksissuedvalue": 1459445,
    "dividendpayables": 30495,
    "unusedtaxlossesforwhichnodeferredtaxassetrecognised": 1873000,
    "cashonhand": 1254,
    "confidenceinterval": 0.01,
    "valueatrisk": 13,
    "othercurrentpayables": 404187,
    "debtextinguishment": 342501,
    "issuanceofunitsforsettlementofdebt": 889612,
    "descriptionofunitissued": "Each Unit consists of one common share in the capital of the Company (each, a \"Share\") and one-half of one common share purchase warrant (each whole warrant, a \"Warrant\").",
    "depreciationrate": 0.3,
    "depreciationpropertyplantandequipment": 839,
    "tradeandotherpayablestorelatedparties": 211833,
    "transfersofresearchanddevelopmentfromentityrelatedpartytransactions": 25000,
    "servicesreceivedrelatedpartytransactions": 25000,
    "keymanagementpersonnelcompensationshorttermemployeebenefits": 329250,
    "directorsremunerationexpense": 79000,
    "keymanagementpersonnelcompensationsharebasedpayment": 62720,
    "keymanagementpersonnelcompensation": 470970,
    "accountingprofit": -743228,
    "applicabletaxrate": 0.27,
    "taxexpenseincomeatapplicabletaxrate": -200672,
    "taxeffectofexpensenotdeductibleindeterminingtaxableprofittaxloss": 29000,
    "taxeffectofchangeinunrecognizeddeferredtaxassets": 229672,
    "netdeferredtaxassets": -10816000,
    "royaltypayable": 21670400,
    "financialliabilities": 27062354,
    "warrantsterm": "three years",
    "descriptionofloanforgiveness": "Repayment of $40,000 by December 31, 2023 results in a $20,000 loan forgiveness.",
    "termofloan": 3,
    "borrowingsinterestrate": 0.05,
    "estimatedinitialcarryingvalueofloan": 26663,
    "debtinstrumentdiscountrate": 0.18,
    "loanliability": 13378,
    "revenuefromroyalties": 16000000,
    "royaltydescription": "Under this royalty arrangement, RepliCel has provided Mainepointe with a right to participate in RepliCel's royalty revenue stream up to a maximum payout of USD$16 million and certain distribution rights of RepliCel Injector Product Line in the United States. Management is required to make an estimate to determine the timing of the Company's royalty revenue stream up to USD$16 million.",
    "dividendsreceived": 30495,
    "accretionsonpreferenceshares": 47409,
    "estimatedpaybackperiod": 10,
    "royaltypayableestimate": 2810512,
    "royaltyeffectiveinterestrate": 0.21,
    "numberofaggregatecommonshare": 4000000,
    "amountofinvestmentmade": 500000,
    "commonstockpricepershare": 0.675,
    "aggregatemaximumamountofroyalty": 16000000,
    "usmarketexpirationperiod": 4,
    "revenuefromsaleofproducts": 2000000,
    "netpresentvalueofprofitearn": 2000000,
    "percentageofearnedamountpaidfromsaleofnbdsproducts": 0.05,
    "percentageofearnedamountpaidfromsaleofdscproducts": 0.2,
    "royaltypayableclassifiedasfinancialliability": 16000000,
    "accretionexpense": 2031758,
    "royaltypayableaccretion": 2031758,
    "royaltypayablechangeinestimate": -3310875,
    "royaltypayableforeignexchange": 253024
  },
  {
    "date": "2021-12-31",
    "symbol": "REPCF",
    "period": "FY",
    "entityregistrantname": "REPLICEL LIFE SCIENCES INC.",
    "entitycentralindexkey": 1205059,
    "documentperiodenddate": "                                                December 31, 2021                                            ",
    "documenttype": "20-F",
    "currentfiscalyearenddate": "December 31",
    "amendmentflag": "false",
    "documentfiscalperiodfocus": "FY",
    "documentfiscalyearfocus": 2021,
    "entitycurrentreportingstatus": "Yes",
    "entityfilercategory": "Non-accelerated filer",
    "documentannualreport": "true",
    "documenttransitionreport": "[ ]",
    "documentregistrationstatement": "[ ]",
    "documentshellcompanyreport": "[ ]",
    "entityfilenumber": "000-50112",
    "entityincorporationstatecountrycode": "British Columbia",
    "entitywellknownseasonedissuer": "No",
    "entityvoluntaryfilers": "No",
    "entityinteractivedatacurrent": "Yes",
    "entityemerginggrowthcompany": "[ ]",
    "entityshellcompany": "NO",
    "contactpersonnelname": "Lee Buckler,",
    "cityareacode": 604,
    "localphonenumber": "248-8730",
    "entityaddressaddressline1": "Suite 900 - 570 Granville Street",
    "entityaddresscityortown": "Vancouver",
    "entityaddressstateorprovince": "British Columbia",
    "entityaddresscountry": "Canada",
    "entityaddresspostalzipcode": "V6C 3P1",
    "contactpersonnelfaxnumber": "(604) 248-8690",
    "documentaccountingstandard": "International Financial Reporting Standards",
    "auditorname": "BDO Canada LLP",
    "auditorlocation": "Vancouver, British Columbia",
    "auditorfirmid": 1227,
    "cashandcashequivalents": 221188,
    "shortterminvestmentsclassifiedascashequivalents": 17250,
    "currenttaxassetscurrent": 25867,
    "currentprepaidexpenses": 93363,
    "currentcontractassets": 35374,
    "currentassets": 393042,
    "noncurrentcontractassets": 195475,
    "propertyplantandequipment": 1836,
    "assets": 591794,
    "tradeandothercurrentpayables": 708563,
    "currentcontractliabilities": 353735,
    "preferenceshares": 958430,
    "currentliabilities": 1673684,
    "longtermborrowings": 42709,
    "deferredgovernmentgrantincomenoncurrent": 8454,
    "noncurrentputliability": 3393337,
    "noncurrentcontractliabilities": 1954746,
    "noncurrentroyaltypayable": 2649181,
    "liabilities": 7434173,
    "issuedcapital": 30291486,
    "additionalpaidincapital": 5097777,
    "retainedearnings": -42231642,
    "equity": -42231642,
    "equityandliabilities": 591794,
    "licencefeeincome": 353735,
    "researchanddevelopmentexpense": 1149170,
    "sellinggeneralandadministrativeexpense": 1505873,
    "profitlossfromoperatingactivities": -2301308,
    "accretiononpreferenceshares": 141350,
    "accretiononcebaloan": 5528,
    "accretiononputliability": 219236,
    "accretiononroyaltypayable": 291122,
    "gainslossesonexchangedifferencesontranslationrecognisedinprofitorloss": -45741,
    "gainlossondebtsettlement": 31137,
    "revenuefromgovernmentgrants": 2819,
    "lossonremeasurementofderivativeliability": 55501,
    "investmentincome": 69,
    "profitloss": -4073315,
    "dilutedearningslosspershare": -0.13,
    "adjustedweightedaverageshares": 32486770,
    "adjustmentsforaccretionandaccrueddividends": 141350,
    "adjustmentsforamortizationofcontractasset": 35372,
    "revenuefromcontractliability": 353738,
    "adjustmentsfordepreciationandamortisationexpense": 1148,
    "adjustmentsforsharebasedpayments": 471756,
    "adjustmentsfordecreaseincreaseinsalestaxesrecoverable": 2376,
    "adjustmentsfordecreaseincreaseinprepaidexpensesanddeposits": -22903,
    "adjustmentsforincreasedecreaseintradeaccountpayable": -300890,
    "adjustmentsforincreasedecreaseindeferredgovernmentgrant": -2819,
    "cashflowsfromusedinoperatingactivities": -2513859,
    "grossproceedsfrominvestment": 2698884,
    "proceedsfromexerciseofwarrants": 1800,
    "cashflowsfromusedinfinancingactivities": 2700684,
    "increasedecreaseincashandcashequivalents": 186825,
    "numberofsharesoutstanding": 34959207,
    "increasedecreasethroughsharesissuedsix": 1459445,
    "increasedecreasethroughsharesissuedsharessix": 3986684,
    "increasedecreasethroughsharesissuedfive": 1800,
    "increasedecreasethroughsharesissuedsharesfive": 5000,
    "increasedecreasethroughsharesissuednine": 311364,
    "increasedecreasethroughsharesissuedsharesnine": 889612,
    "increasedecreasethroughsharesissuedfour": 47737,
    "increasedecreasethroughsharesissuedsharesfour": 126492,
    "increasedecreasethroughsharebasedpaymenttransactions": 471755,
    "descriptionofriskfreeinterestrateshareoptionsgranted": 0.025400000000000002,
    "descriptionofoptionlifeshareoptionsgranted": 5,
    "descriptionofexpectedvolatilityshareoptionsgranted": 1.1300000000000001,
    "exercisepriceshareoptionsgranted2019": 0.4,
    "grantdatefairvalue": 0.32,
    "numberofoutstandingshareoptions": 2825000,
    "weightedaverageexercisepriceofshareoptionsoutstandinginsharebasedpaymentarrangement2019": 0.43,
    "numberofshareoptionsgrantedinsharebasedpaymentarrangement": 1715000,
    "weightedaverageexercisepriceofshareoptionsgrantedinsharebasedpaymentarrangement2019": 0.4,
    "numberofshareoptionsexpiredinsharebasedpaymentarrangement": 620000,
    "weightedaverageexercisepriceofshareoptionsexpiredinsharebasedpaymentarrangement2019": 0.66,
    "numberofshareoptionsexercisableinsharebasedpaymentarrangement": 2007500,
    "weightedaverageexercisepriceofshareoptionsexercisableinsharebasedpaymentarrangement2019": 0.42,
    "numberofoutstandingwarrants": 1819555,
    "weightedaverageexercisepriceofwarrantsoutstandinginsharebasedpaymentarrangement": 0.36,
    "numberofwarrantsexpiredinsharebasedpaymentarrangement": 5000,
    "weightedaverageexercisepriceofwarrantsexpiredinsharebasedpaymentarrangement": 0.36,
    "guaranteedinvestmentcertificateinterestrate": 0.022000000000000002,
    "securitiesexcludedfromcomputationofearningspershareamount": 1819555,
    "preferencesharesredemptionperiod": 5,
    "preferencestockredemptionpricepershare": 0.74,
    "putliabilityaccretionexpense": 219236,
    "numberofsharesissued": 34959207,
    "numberofsharesissuedsubjecttoputoption": 1785967,
    "descriptionofstockoptionplan": "On May 21, 2014, the Company approved a Stock Option Plan whereby the Company may grant stock options to directors, officers, employees and consultants. The maximum number of shares reserved for issue under the plan cannot exceed 10% of the outstanding common shares of the Company as at the date of the grant. The stock options can be exercisable for a maximum of 10 years from the grant date and with various vesting terms.",
    "weightedaverageremainingcontractuallifeofoutstandingshareoptions2019": 3.33,
    "unrecognizedstockbasedcompensation": 84033,
    "increasedecreaseinnumberofordinarysharesissued": 3986684,
    "commanstocksissuedvalue": 1459445,
    "dividendpayables": 6825,
    "unusedtaxlossesforwhichnodeferredtaxassetrecognised": 440000,
    "cashonhand": 40740,
    "confidenceinterval": 0.01,
    "valueatrisk": 407,
    "othercurrentpayables": 219384,
    "debtextinguishment": 342501,
    "issuanceofunitsforsettlementofdebt": 889612,
    "depreciationrate": 0.3,
    "depreciationpropertyplantandequipment": 1148,
    "tradeandotherpayablestorelatedparties": 106583,
    "transfersofresearchanddevelopmentfromentityrelatedpartytransactions": 48404,
    "servicesreceivedrelatedpartytransactions": 48404,
    "keymanagementpersonnelcompensationshorttermemployeebenefits": 336000,
    "directorsremunerationexpense": 75083,
    "keymanagementpersonnelcompensationsharebasedpayment": 382442,
    "keymanagementpersonnelcompensation": 793525,
    "accountingprofit": -4073315,
    "applicabletaxrate": 0.27,
    "taxexpenseincomeatapplicabletaxrate": -1099000,
    "taxeffectofexpensenotdeductibleindeterminingtaxableprofittaxloss": 318000,
    "taxeffectofchangeinunrecognizeddeferredtaxassets": 781000,
    "netdeferredtaxassets": -10587000,
    "royaltypayable": 20284800,
    "financialliabilities": 25387839,
    "numberofcommonsharessubscribed": 1125500,
    "valueofcommonsharessubscribed": 202590,
    "descriptionofloanforgiveness": "Repayment of $40,000 by December 31, 2022 results in a $20,000 loan forgiveness.",
    "termofloan": 3,
    "borrowingsinterestrate": 0.05,
    "estimatedinitialcarryingvalueofloan": 26663,
    "debtinstrumentdiscountrate": 0.18,
    "loanliability": 13378,
    "revenuefromroyalties": 16000000,
    "royaltydescription": "Under this royalty arrangement, RepliCel has provided Mainepointe with a right to participate in RepliCel's royalty revenue stream up to a maximum payout of $16 million US and certain distribution rights of RepliCel Injector Product Line in the United States. Management is required to make an estimate to determine the timing of the Company's royalty revenue stream up to $16 million US.",
    "dividendsreceived": 30495,
    "accretionsonpreferenceshares": 110855,
    "dividendspaidordinaryshares": 47737,
    "amountoftranche": 2698884,
    "amountofsharecapitalandsharesubscription": 1459445,
    "derivativefinancialliabilities": -55501,
    "royaltyeffectiveinterestrate": 0.25,
    "royaltypayableestimate": 2203707,
    "estimatedpaybackperiod": 10,
    "numberofaggregatecommonshare": 4000000,
    "amountofinvestmentmade": 500000,
    "usmarketexpirationperiod": 4,
    "revenuefromsaleofproducts": 2000000,
    "netpresentvalueofprofitearn": 2000000,
    "percentageofearnedamountpaidfromsaleofnbdsproducts": 0.05,
    "percentageofearnedamountpaidfromsaleofdscproducts": 0.2,
    "royaltypayableclassifiedasfinancialliability": 16000000,
    "accretionexpense": 732069,
    "accretionexchangeloss": 15565
  },
  {
    "date": "2020-12-31",
    "symbol": "REPCF",
    "period": "FY",
    "entityregistrantname": "REPLICEL LIFE SCIENCES INC.",
    "entitycentralindexkey": 1205059,
    "documenttype": "20-F",
    "amendmentflag": "false",
    "documentperiodenddate": "2020-12-31",
    "currentfiscalyearenddate": "--12-31",
    "entityfilercategory": "Non-accelerated Filer",
    "entitycurrentreportingstatus": "Yes",
    "entityvoluntaryfilers": "No",
    "entitywellknownseasonedissuer": "No",
    "documentfiscalyearfocus": 2020,
    "documentfiscalperiodfocus": "FY",
    "entityemerginggrowthcompany": "false",
    "entityshellcompany": "false",
    "entityinteractivedatacurrent": "Yes",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentshellcompanyreport": "false",
    "cashandcashequivalents": 34363,
    "shortterminvestmentsclassifiedascashequivalents": 17250,
    "currenttaxassetscurrent": 28243,
    "currentprepaidexpenses": 70460,
    "currentcontractassets": 35374,
    "currentassets": 185690,
    "noncurrentcontractassets": 230847,
    "propertyplantandequipment": 2623,
    "assets": 420962,
    "tradeandothercurrentpayables": 1359449,
    "currentcontractliabilities": 353735,
    "preferenceshares": 958430,
    "currentpromissorynotepayable": 47299,
    "currentliabilities": 2239027,
    "longtermborrowings": 40000,
    "deferredgovernmentgrantincomenoncurrent": 11273,
    "noncurrentputliability": 3393337,
    "noncurrentcontractliabilities": 2308484,
    "liabilities": 5482128,
    "issuedcapital": 28471140,
    "additionalpaidincapital": 4626021,
    "retainedearnings": -38158327,
    "equity": -38158327,
    "equityandliabilities": 420962,
    "licencefeeincome": 353735,
    "researchanddevelopmentexpense": 819403,
    "sellinggeneralandadministrativeexpense": 884704,
    "profitlossfromoperatingactivities": -1350372,
    "accretiononpreferenceshares": 68486,
    "accretiononputliability": 176085,
    "gainslossesonexchangedifferencesontranslationrecognisedinprofitorloss": -8605,
    "gainlossondebtsettlement": 800,
    "revenuefromgovernmentgrants": 22105,
    "investmentincome": 358,
    "profitloss": -1580285,
    "basicanddilutedearningslosspershare": -0.06,
    "adjustedweightedaverageshares": 26961067,
    "adjustmentsforaccretionandaccrueddividends": 68486,
    "adjustmentsforamortizationofcontractasset": 35374,
    "adjustmentsforgovernmentassistance": 31273,
    "revenuefromcontractliability": 353735,
    "adjustmentsfordepreciationandamortisationexpense": 1574,
    "adjustmentsforsharebasedpayments": 3397,
    "adjustmentsfordecreaseincreaseinsalestaxesrecoverable": -11719,
    "adjustmentsfordecreaseincreaseinprepaidexpensesanddeposits": 58210,
    "adjustmentsforincreasedecreaseintradeaccountpayable": 858207,
    "adjustmentsforincreasedecreaseindeferredgovernmentgrant": 11273,
    "cashflowsfromusedinoperatingactivities": -765206,
    "cashflowsfromusedindecreaseincreaseinshorttermdepositsandinvestments": 11500,
    "cashflowsfromusedininvestingactivities": 11500,
    "proceedsfromgovernmentgrantsclassifiedasfinancingactivities": 60000,
    "proceedsfromissuingshares": 656840,
    "proceedsfromissueofpreferenceshares": 130000,
    "proceedsfromnoncurrentborrowings": 47299,
    "cashflowsfromusedinfinancingactivities": 764139,
    "increasedecreaseincashandcashequivalents": 10434,
    "numberofsharesoutstanding": 29951419,
    "issueofequity": 656840,
    "increasedecreaseinnumberofsharesoutstanding": 325000,
    "increasedecreasethroughsharesissuedtwo": 256769,
    "increasedecreasethroughsharesissuedsharestwo": 1426491,
    "increasedecreasethroughsharesissuedthree": 28000,
    "increasedecreasethroughsharesissuedsharesthree": 160000,
    "increasedecreasethroughsharebasedpaymenttransactions": 3397,
    "numberofoutstandingshareoptions": 1730000,
    "weightedaverageexercisepriceofshareoptionsoutstandinginsharebasedpaymentarrangement2019": 8.5,
    "numberofshareoptionsforfeitedinsharebasedpaymentarrangement": 100000,
    "weightedaverageexercisepriceofshareoptionsforfeitedinsharebasedpaymentarrangement2019": 0.52,
    "numberofshareoptionsexercisableinsharebasedpaymentarrangement": 1730000,
    "weightedaverageexercisepriceofshareoptionsexercisableinsharebasedpaymentarrangement2019": 0.51,
    "numberofoutstandingwarrants": 1824555,
    "weightedaverageexercisepriceofwarrantsoutstandinginsharebasedpaymentarrangement": 0.36,
    "numberofwarrantsexpiredinsharebasedpaymentarrangement": 3793184,
    "weightedaverageexercisepriceofwarrantsexpiredinsharebasedpaymentarrangement": 1.7,
    "numberofwarrantsgrantedinsharebasedpaymentarrangement": 1824555,
    "weightedaverageexercisepriceofwarrantsgrantedinsharebasedpaymentarrangement": 0.36,
    "guaranteedinvestmentcertificateinterestrate": 0.022,
    "securitiesexcludedfromcomputationofearningspershareamount": 1824555,
    "preferencesharesredemptionperiod": "P5Y",
    "preferencestockredemptionpricepershare": 0.74,
    "numberofsharesissued": 33523307,
    "descriptionofstockoptionplan": "On May 21, 2014, the Company approved a Stock Option Plan whereby the Company may grant stock options to directors, officers, employees and consultants. The maximum number of shares reserved for issue under the plan cannot exceed 10% of the outstanding common shares of the Company as at the date of the grant. The stock options can be exercisable for a maximum of 10 years from the grant date and with various vesting terms.",
    "weightedaverageremainingcontractuallifeofoutstandingshareoptions2019": "P2Y",
    "unusedtaxlossesforwhichnodeferredtaxassetrecognised": 31395000,
    "cashonhand": 13,
    "confidenceinterval": 0.01,
    "valueatrisk": 1,
    "othercurrentpayables": 358507,
    "debtextinguishment": 284769,
    "issuanceofunitsforsettlementofdebt": 1586491,
    "dividendpayables": 11881,
    "depreciationrate": 0.3,
    "depreciationpropertyplantandequipment": 1574,
    "tradeandotherpayablestorelatedparties": 263405,
    "transfersofresearchanddevelopmentfromentityrelatedpartytransactions": 48358,
    "servicesreceivedrelatedpartytransactions": 48358,
    "keymanagementpersonnelcompensationshorttermemployeebenefits": 336000,
    "directorsremunerationexpense": 71250,
    "keymanagementpersonnelcompensationsharebasedpayment": 3397,
    "keymanagementpersonnelcompensation": 410647,
    "accountingprofit": -1580285,
    "applicabletaxrate": 0.27,
    "taxexpenseincomeatapplicabletaxrate": -426677,
    "taxeffectofexpensenotdeductibleindeterminingtaxableprofittaxloss": 17000,
    "taxeffectofchangeinunrecognizeddeferredtaxassets": 443677,
    "netdeferredtaxassets": -9806000,
    "noncurrentpromissorynotepayable": 47299,
    "financialliabilities": 5798515,
    "numberofcommonsharessubscribed": 1125500,
    "valueofcommonsharessubscribed": 202590,
    "descriptionofloanforgiveness": "Repayment of $40,000 by December 31, 2022 results in a $20,000 loan forgiveness.",
    "termofloan": "P3Y",
    "borrowingsinterestrate": 0.05,
    "estimatedinitialcarryingvalueofloan": 26663,
    "debtinstrumentdiscountrate": 0.18,
    "loanliability": 13378,
    "interestexpense": 2105
  },
  {
    "date": "2019-12-31",
    "symbol": "REPCF",
    "period": "FY",
    "entityregistrantname": "REPLICEL LIFE SCIENCES INC.",
    "entitycentralindexkey": 1205059,
    "documenttype": "20-F",
    "amendmentflag": "false",
    "documentperiodenddate": "2019-12-31",
    "currentfiscalyearenddate": "--12-31",
    "entityfilercategory": "Non-accelerated Filer",
    "entitycurrentreportingstatus": "Yes",
    "entityvoluntaryfilers": "No",
    "entitywellknownseasonedissuer": "No",
    "documentfiscalyearfocus": 2019,
    "documentfiscalperiodfocus": "FY",
    "entityemerginggrowthcompany": "false",
    "entityshellcompany": "false",
    "entityinteractivedatacurrent": "Yes",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentshellcompanyreport": "false",
    "cashandcashequivalents": 23929,
    "shortterminvestmentsclassifiedascashequivalents": 28750,
    "currenttaxassetscurrent": 16524,
    "currentprepaidexpenses": 128670,
    "currentcontractassets": 25261,
    "currentassets": 223134,
    "noncurrentcontractassets": 189976,
    "propertyplantandequipment": 3746,
    "assets": 419109,
    "tradeandothercurrentpayables": 741313,
    "currentcontractliabilities": 252609,
    "preferenceshares": 449287,
    "currentliabilities": 1449479,
    "noncurrentcontractliabilities": 1899754,
    "liabilities": 3349233,
    "issuedcapital": 28960095,
    "additionalpaidincapital": 4622624,
    "retainedearnings": -36512843,
    "equity": -36512843,
    "equityandliabilities": 419109,
    "licencefeeincome": 252609,
    "researchanddevelopmentexpense": 2196364,
    "sellinggeneralandadministrativeexpense": 1074100,
    "profitlossfromoperatingactivities": -3017855,
    "accretiononpreferenceshares": 33289,
    "gainslossesonexchangedifferencesontranslationrecognisedinprofitorloss": -9997,
    "gainlossondebtsettlement": 107395,
    "profitloss": -2953746,
    "basicanddilutedearningslosspershare": -0.11,
    "adjustedweightedaverageshares": 27679504,
    "adjustmentsforamortizationofcontractasset": 25261,
    "revenuefromcontractliability": 252609,
    "adjustmentsfordepreciationandamortisationexpense": 2168,
    "adjustmentsforsharebasedpayments": 26275,
    "adjustmentsfordecreaseincreaseinsalestaxesrecoverable": 32980,
    "adjustmentsfordecreaseincreaseinprepaidexpensesanddeposits": 382071,
    "adjustmentsforincreasedecreaseintradeaccountpayable": 29866,
    "cashflowsfromusedinoperatingactivities": -2781840,
    "cashflowsfromusedindecreaseincreaseinshorttermdepositsandinvestments": -28750,
    "cashflowsfromusedininvestingactivities": -28750,
    "proceedsfromissueofpreferenceshares": 415998,
    "cashflowsfromusedinfinancingactivities": 415998,
    "increasedecreaseincashandcashequivalents": -2394592,
    "numberofsharesoutstanding": 28287751,
    "issueofequity": 257187,
    "increasedecreaseinnumberofsharesoutstanding": 735904,
    "increasedecreasethroughsharesissued": 195343,
    "increasedecreasethroughsharesissuedshares": 751318,
    "increasedecreasethroughsharebasedpaymenttransactions": 26275,
    "numberofoutstandingshareoptions": 1830000,
    "weightedaverageexercisepriceofshareoptionsoutstandinginsharebasedpaymentarrangement2019": 8.5,
    "numberofshareoptionsgrantedinsharebasedpaymentarrangement": 1110000,
    "numberofshareoptionsforfeitedinsharebasedpaymentarrangement": 250000,
    "weightedaverageexercisepriceofshareoptionsforfeitedinsharebasedpaymentarrangement2019": 0.91,
    "numberofshareoptionsexercisableinsharebasedpaymentarrangement": 1755000,
    "weightedaverageexercisepriceofshareoptionsexercisableinsharebasedpaymentarrangement2019": 0.79,
    "numberofoutstandingwarrants": 3793184,
    "weightedaverageexercisepriceofwarrantsoutstandinginsharebasedpaymentarrangement": 1.7,
    "guaranteedinvestmentcertificateinterestrate": 0.027,
    "securitiesexcludedfromcomputationofearningspershareamount": 3793184,
    "preferencesharesredemptionperiod": "P5Y",
    "preferencestockredemptionpricepershare": 0.74,
    "descriptionofstockoptionplan": "On May 21, 2014, the Company approved a Stock Option Plan whereby the Company may grant stock options to directors, officers, employees and consultants.&#160; The maximum number of shares reserved for issue under the plan cannot exceed 10% of the outstanding common shares of the Company as at the date of the grant. The stock options can be exercisable for a maximum of 10 years from the grant date and with various vesting terms.",
    "weightedaverageremainingcontractuallifeofoutstandingshareoptions2019": "P2Y10M17D",
    "unrecognizedstockbasedcompensation": 3409,
    "unusedtaxlossesforwhichnodeferredtaxassetrecognised": 3407000,
    "cashonhand": 605,
    "confidenceinterval": 0.01,
    "valueatrisk": 6,
    "othercurrentpayables": 186220,
    "debtextinguishment": 559924,
    "issuanceofunitsforsettlementofdebt": 1487222,
    "depreciationrate": 0.3,
    "depreciationpropertyplantandequipment": 2168,
    "tradeandotherpayablestorelatedparties": 107302,
    "transfersofresearchanddevelopmentfromentityrelatedpartytransactions": 166023,
    "servicesreceivedrelatedpartytransactions": 166023,
    "keymanagementpersonnelcompensationshorttermemployeebenefits": 336000,
    "directorsremunerationexpense": 70500,
    "keymanagementpersonnelcompensationsharebasedpayment": 26275,
    "keymanagementpersonnelcompensation": 432775,
    "accountingprofit": -2953746,
    "applicabletaxrate": 0.27,
    "taxexpenseincomeatapplicabletaxrate": -797000,
    "taxeffectofexpensenotdeductibleindeterminingtaxableprofittaxloss": 48000,
    "taxeffectofchangeinunrecognizeddeferredtaxassets": 845000,
    "netdeferredtaxassets": -9363000,
    "financialliabilities": 1190600,
    "otherfeeandcommissionexpense": 19652
  },
  {
    "date": "2018-12-31",
    "symbol": "REPCF",
    "period": "FY",
    "documenttype": "20-F",
    "amendmentflag": "false",
    "documentperiodenddate": "2018-12-31",
    "tradingsymbol": "repcf",
    "entityregistrantname": "REPLICEL LIFE SCIENCES INC.",
    "entitycentralindexkey": 1205059,
    "currentfiscalyearenddate": "--12-31",
    "entityfilercategory": "Non-accelerated Filer",
    "entitycommonstocksharesoutstanding": 26800529,
    "entitycurrentreportingstatus": "Yes",
    "entityvoluntaryfilers": "No",
    "entitywellknownseasonedissuer": "No",
    "documentfiscalyearfocus": 2018,
    "documentfiscalperiodfocus": "FY",
    "entityemerginggrowthcompany": "false",
    "entityshellcompany": "false",
    "cashandcashequivalents": 2418521,
    "currenttaxassetscurrent": 49504,
    "currentprepaidexpenses": 510741,
    "currentcontractassets": 25261,
    "currentassets": 3004027,
    "noncurrentcontractassets": 215237,
    "propertyplantandequipment": 47833,
    "assets": 3227431,
    "tradeandothercurrentpayables": 1277642,
    "currentcontractliabilities": 252609,
    "currentliabilities": 1530251,
    "noncurrentcontractliabilities": 2152363,
    "liabilities": 3682614,
    "issuedcapital": 28745992,
    "additionalpaidincapital": 4357922,
    "retainedearnings": -33559097,
    "equity": -33559097,
    "equityandliabilities": 3227431,
    "licencefeeincome": 121114,
    "researchanddevelopmentexpense": 709260,
    "sellinggeneralandadministrativeexpense": 2151154,
    "profitlossfromoperatingactivities": -2739300,
    "gainslossesonexchangedifferencesontranslationrecognisedinprofitorloss": -29817,
    "investmentincome": 37,
    "profitloss": -2769080,
    "basicanddilutedearningslosspershare": -0.12,
    "adjustedweightedaverageshares": 22661001,
    "adjustmentsforamortizationofcontractasset": 12111,
    "adjustmentsfordepreciationandamortisationexpense": 2998,
    "adjustmentsforsharebasedpayments": 326367,
    "adjustmentsfordecreaseincreaseinsalestaxesrecoverable": -962,
    "adjustmentsfordecreaseincreaseinprepaidexpensesanddeposits": -221515,
    "adjustmentsforcontractasset": -252609,
    "adjustmentsforincreasedecreaseintradeaccountpayable": 111619,
    "adjustmentsforcontractliability": -2404972,
    "cashflowsfromusedinoperatingactivities": -386099,
    "proceedsfromissuingshares": 2563919,
    "paymentsforshareissuecosts": 256392,
    "cashflowsfromusedinfinancingactivities": 2307527,
    "increasedecreaseincashandcashequivalents": 1921428,
    "numberofsharesoutstanding": 26800529,
    "issueofequity": 2563919,
    "increasedecreaseinnumberofsharesoutstanding": 5357900,
    "shareissuerelatedcost": -256392,
    "increasedecreasethroughsharebasedpaymenttransactions": 326367,
    "descriptionofriskfreeinterestrateshareoptionsgranted": 0.0231,
    "descriptionofoptionlifeshareoptionsgranted": 2,
    "descriptionofexpectedvolatilityshareoptionsgranted": 1.04,
    "exercisepriceshareoptionsgranted": 0.95,
    "grantdatefairvalue": 0.45,
    "numberofoutstandingshareoptions": 2080000,
    "weightedaverageexercisepriceofshareoptionsoutstandinginsharebasedpaymentarrangement": 1.64,
    "numberofshareoptionsgrantedinsharebasedpaymentarrangement": 1110000,
    "weightedaverageexercisepriceofshareoptionsgrantedinsharebasedpaymentarrangement": 0.43,
    "numberofshareoptionsforfeitedinsharebasedpaymentarrangement": 430000,
    "weightedaverageexercisepriceofshareoptionsforfeitedinsharebasedpaymentarrangement": 0.69,
    "numberofshareoptionsexercisableinsharebasedpaymentarrangement": 1905000,
    "weightedaverageexercisepriceofshareoptionsexercisableinsharebasedpaymentarrangement": 0.82,
    "numberofoutstandingwarrants": 2721604,
    "weightedaverageexercisepriceofwarrantsoutstandinginsharebasedpaymentarrangement": 2,
    "numberofwarrantsgrantedinsharebasedpaymentarrangement": 1071580,
    "weightedaverageexercisepriceofwarrantsgrantedinsharebasedpaymentarrangement": 0.95,
    "numberofwarrantsexpiredinsharebasedpaymentarrangement": 10027294,
    "weightedaverageexercisepriceofwarrantsexpiredinsharebasedpaymentarrangement": 0.83,
    "securitiesexcludedfromcomputationofearningspershareamount": 3793183,
    "incrementalfairvaluegrantedmodifiedsharebasedpaymentarrangements": 3.1,
    "commonsharesnotsubjecttoescrowprovisionsfullyvested": 100000,
    "descriptionofstockoptionplan": "On May 21, 2014, the Company approved a Stock Option Plan whereby the Company may grant stock options to directors, officers, employees and consultants. The maximum number of shares reserved for issue under the plan cannot exceed 10% of the outstanding common shares of the Company as at the date of the grant. The stock options can be exercisable for a maximum of 10 years from the grant date and with various vesting terms.",
    "weightedaverageremainingcontractuallifeofoutstandingshareoptions": 4.56,
    "optionsexercisablepricepershare": 1,
    "numberofshareoptionsexercisedinsharebasedpaymentarrangement": 200000,
    "unusedtaxlossesforwhichnodeferredtaxassetrecognised": 2790000,
    "applicabletaxrate": 0.12,
    "cashonhand": 11069,
    "confidenceinterval": 0.01,
    "valueatrisk": 111,
    "depreciationrate": 0.3,
    "depreciationpropertyplantandequipment": 2998,
    "tradeandotherpayablestorelatedparties": 512140,
    "transfersofresearchanddevelopmentfromentityrelatedpartytransactions": 125000,
    "generalandadministrativeexpense": 247000,
    "servicesreceivedrelatedpartytransactions": 372000,
    "keymanagementpersonnelcompensationshorttermemployeebenefits": 380435,
    "directorsremunerationexpense": 54750,
    "keymanagementpersonnelcompensationsharebasedpayment": 293367,
    "keymanagementpersonnelcompensation": 728552,
    "accountingprofit": -2769080,
    "taxexpenseincomeatapplicabletaxrate": -748000,
    "taxeffectofstockbasedcompensation": 88000,
    "taxeffectofexpensenotdeductibleindeterminingtaxableprofittaxloss": 26000,
    "othertaxeffectsforreconciliationbetweenaccountingprofitandtaxexpenseincome": 32000,
    "taxeffectofchangeinunrecognizeddeferredtaxassets": 718000,
    "netdeferredtaxassets": -8518000
  }
]